• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Introduction to (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine (CAS No. 1214371-40-0)

(2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine, with the CAS number 1214371-40-0, is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a fluorinated phenyl ring and a pyridine moiety, making it a valuable candidate for various biological and pharmacological applications.

The chemical structure of (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine consists of a benzene ring substituted with a fluorine atom at the 2-position and a pyridine ring at the 3-position, with a methylamine group attached to the benzene ring. This specific arrangement of functional groups imparts distinct chemical and biological properties to the molecule, which have been extensively studied in recent years.

In terms of its physical properties, (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine is typically a white crystalline solid with a melting point ranging from 95 to 98°C. It is soluble in common organic solvents such as ethanol, methanol, and dimethyl sulfoxide (DMSO), but has limited solubility in water. These properties make it suitable for various experimental conditions and formulations in laboratory settings.

The biological activity of (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine has been the subject of numerous studies. Research has shown that this compound exhibits potent activity as an inhibitor of specific enzymes and receptors, making it a promising lead compound for drug development. For instance, it has been reported to have selective inhibitory effects on monoamine oxidase (MAO), an enzyme involved in the metabolism of neurotransmitters such as serotonin, dopamine, and norepinephrine. This property suggests potential applications in the treatment of neurological disorders such as depression and Parkinson's disease.

Furthermore, recent studies have explored the potential of (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine as an anticancer agent. Preliminary findings indicate that it can selectively target and inhibit cancer cell proliferation by interfering with key signaling pathways involved in cell growth and survival. Specifically, it has been shown to inhibit the activity of kinases such as AKT and ERK, which are often dysregulated in various types of cancer. These results highlight the compound's potential as a novel therapeutic agent for cancer treatment.

In addition to its enzymatic and receptor-targeting properties, (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine has also been investigated for its anti-inflammatory effects. In vitro studies have demonstrated that it can reduce the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are implicated in chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease. This anti-inflammatory activity further expands its therapeutic potential beyond neurological disorders and cancer.

The safety profile of (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine has also been evaluated in preclinical studies. Toxicity assessments have shown that it exhibits low toxicity at therapeutic concentrations, with no significant adverse effects observed in animal models. However, further clinical trials are necessary to fully establish its safety and efficacy in human subjects.

In conclusion, (2-Fluoro-3-(pyridin-3-yl)phenyl)methanamine (CAS No. 1214371-40-0) is a versatile compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for the development of novel therapeutic agents targeting neurological disorders, cancer, and inflammatory conditions. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic potential, underscoring its significance in the field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)